Syngeneic Mouse Models
Syngeneic mouse models represent one of the first steps needed to determine the efficacy of your novel immunotherapies in an in vivo model with functional immune system
InnoSer’s Syngeneic Mouse Model Services
Syngeneic mouse models are established from immortalized murine cancer cells originating from inbred mouse strains that are implanted and grown in genetically identical strains. Avoiding the need to use immunocompromised mice, this approach allows you to study your novel immunotherapy’s efficacy in a mouse model that combines tumor microenvironment interactions with a fully functional immune system.
Therefore, experts at InnoSer recommend the use of syngeneic rodent models (mice or rats) as a first step to evaluate the efficacy of your novel immunotherapy approaches (vaccines, mRNA-based therapeutics, immune checkpoint inhibitors, antibody-drug conjugates, (stem) cell therapy such as CAR-T cell therapy, NK cell therapy, etc., as well as classical anti-tumoral compounds (chemotherapy, radiotherapy). Accordingly, syngeneic mouse models represent an easy-to-use, relatively inexpensive mouse model with short study timelines (2-4 weeks), offering reproducible immune response results. However, for more advanced studies, InnoSer’s experts recommend working with humanized mouse models.
✓ Available as subcutaneous or orthotopic models (fluorescently labeled rodent cell lines or followed-up via ultrasound).
✓ Both murine and rat cell lines are available.
✓ Complementary immuno-oncology in vitro assays and PK/PD profiling services.
Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions most cost-effectively. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio.
Unlock the Right Tools for Your Research.
Explore and compare our oncology platforms to identify the perfect model for your study needs.
Syngeneic Mouse Models Sample Data
Tumor growth curve data from the 4T1 (breast cancer cell line) syngeneic mouse model.
Following initial cell culturing, murine breast cancer cells (4T1 mouse breast cell line) were injected orthotopically (directly into the mammary fat pad) of BALB/C mice. This mouse model is available at InnoSer both as an (A) subcutaneous (4T1) whereby tumor growth is followed via calipers and (B) orthotopic mouse model (4T1-luc) whereby tumor growth is followed via bioluminescent imaging. The model is validated with standard-of-care treatments doxorubicin and gemcitabine.
Tumor growth curve data from the PanO2 (pancreatic cancer cell line) syngeneic mouse model.
Following initial cell culturing, murine pancreatic cancer cells (PanO2 cell line) were injected subcutaneously into the left flank of C57BL/6 mice. Model is validated with standard-of-care treatment gemcitabine (tested at different concentrations).
Tumor growth curve data from the MC38 (colorectal carcinoma) syngeneic mouse model.
Following initial cell culturing, murine colorectal carcinoma cells (MC38 cell line) were injected into the left flank of C57BL/6 mice. The MC38 colorectal carcinoma syngeneic mouse model is available at InnoSer both as (A) subcutaneous and (B) orthotopic model. The model is validated with checkpoint inhibitor anti-PD-1.
Tumor growth curve data from the Renca (renal cell carcinoma) syngeneic mouse model.
Following initial cell culturing, murine renal cell carcinoma cells (Renca cell line) were injected into the left flank of C57BL/6 mice. The renal cell carcinoma Renca syngeneic mouse model is available at InnoSer both as a (A) subcutaneous model and orthotopic (B-C) model. The model is validated with standard-of-care treatment Doxorubicin (different dosages tested). Compared to healthy kidneys (B), kidneys of mice injected with Renca cells (C) lead to increase in total kidney volume and development of lesions which can be longitudinally imaged and quantified.
Key Syngeneic Mouse Models Readouts
The People Behind Your Research
Céline Erens, PhD, Immunology Study Director
An expert team led by our immuno-oncology study director, Céline Erens helps you choose the right tools and set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Oncology Board Members
Prof. Dr. Esther Wolfs
A member of InnoSer’s Scientific Advisory Board, Dr. Wolfs is a leading researcher in stem cell therapy. Currently a professor at the University of Hasselt, Ester uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease type 1A.
MD, PhD Marije Slingerland
A member of InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.
Discover Other Related Oncology Research Models
Stay Curious: More Articles to Explore
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Tumor microenvironment (TME) multiplex immunophenotyping analyses
The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com